Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

Please provide your email address to receive an email when new articles are posted on . Results of the phase 3 CHOICE-01 trial, presented during a ASCO Plenary Series session, specifically showed PFS ...

Please provide your email address to receive an email when new articles are posted on . Patients who received torpialimab in addition to nab-paclitaxel had longer median PFS (8.4 months vs. 5.6 months ...

Kidney cancer, computer illustration. Toripalimab plus axitinib can improve progression-free survival, when compared to sunitinib monotherapy, in patients with treatment-naïve, advanced renal cell ...

The application is supported by data from the phase 2 POLARIS-02 and phase 3 JUPITER-02 studies. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...

The US Food and Drug Administration (FDA) has approved toripalimab-tpzi (Loqtorz, Coherus BioSciences) in combination with cisplatin and gemcitabine for the first-line treatment of adults with ...

The median overall survival was 31.5 months in the disitamab vedotin-toripalimab arm and 16.9 months in the chemotherapy arm. First-line treatment with disitamab vedotin and toripalimab can improve ...

Toripalimab plus chemotherapy significantly improved progression-free survival and overall survival over chemotherapy alone in patients with advanced NSCLC while having a manageable safety profile.

A prospective single-arm phase II study of blank-microsphere transarterial chemoembolization (bTACE) plus lenvatinib (LEN) and sequential microwave ablation (MWA) in patients with large hepatocellular ...

Shanghai Junshi Biosciences (OTCPK:SHJBF) said China's National Medical Products Administration (NMPA) accepted an application seeking expanded approval of toripalimab, in combination with ...

Shanghai Junshi Biosciences (OTCPK:SHJBF) said its medicine toripalimab met the main goal of event-free survival (EFS) in a phase 3 trial to treat patients with a type of non-small cell lung cancer ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener The latest update ...